{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:10:41Z","timestamp":1789035041550,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.7759\/cureus.116039","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:35:28Z","timestamp":1789032928000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors"],"prefix":"10.7759","author":[{"given":"Philip","family":"Branigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vo Nhu Y","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Branigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.5956","article-title":"Diagnosis and treatment of type 2 diabetes in adults","volume":"334","author":"Kalyani RR","year":"2025","unstructured":"Kalyani RR, Neumiller JJ, Maruthur NM, Wexler DJ. Diagnosis and treatment of type 2 diabetes in adults. JAMA. 2025, 334:984-1002. 10.1001\/jama.2025.5956","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad E","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022, 400:1803-1820. 10.1016\/S0140-6736(22)01655-5","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05832-0","article-title":"Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis","volume":"66","author":"Morton JI","year":"2023","unstructured":"Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z, Magliano DJ. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023, 66:642-656. 10.1007\/s00125-022-05832-0","journal-title":"Diabetologia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown E","year":"2021","unstructured":"Brown E, Heerspink HL, Cuthbertson DJ, Wilding JH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021, 398:262-276. 10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.056","article-title":"Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar","volume":"75","author":"Wilcox T","year":"2020","unstructured":"Wilcox T, De Block C, Schwartzbard AZ, Newman JD. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar. J Am Coll Cardiol. 2020, 75:1956-1974. 10.1016\/j.jacc.2020.02.056","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-2128. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Rajagopalan S","year":"2017","unstructured":"Rajagopalan S, Brook R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:2098-2099. 10.1056\/NEJMc1712572","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-357. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-1424. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-1098. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-2306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-1446. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-127. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-322. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-1844. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-121. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians","volume":"177","author":"Qaseem A","year":"2024","unstructured":"Qaseem A, Obley AJ, Shamliyan T, et al.. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians. Ann Intern Med. 2024, 177:658-666. 10.7326\/M23-2788","journal-title":"Ann Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das SR","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, et al.. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020, 76:1117-1145. 10.1016\/j.jacc.2020.05.037","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetes Care. 2022, 45:2753-2786. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association","volume":"142","author":"Rangaswami J","year":"2020","unstructured":"Rangaswami J, Bhalla V, de Boer IH, et al.. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020, 142:e265-e286. 10.1161\/CIR.0000000000000920","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo EM","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, et al.. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024, 12:545-557. 10.1016\/S2213-8587(24)00155-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Castellana M","year":"2019","unstructured":"Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, Giorgino F. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis. Sci Rep. 2019, 9:19351. 10.1038\/s41598-019-55524-w","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06565-6","article-title":"Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies","volume":"69","author":"Colombijn JM","year":"2026","unstructured":"Colombijn JM, de Leijer JF, Visseren FL, et al.. Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia. 2026, 69:36-49. 10.1007\/s00125-025-06565-6","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838277","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Li C","year":"2022","unstructured":"Li C, Luo J, Jiang M, Wang K. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022, 13:838277. 10.3389\/fphar.2022.838277","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann JF","year":"2024","unstructured":"Mann JF, Rossing P, Bakris G, et al.. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024, 30:2849-2856. 10.1038\/s41591-024-03133-0","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000902","article-title":"A target trial emulation study of SGLT2 inhibitors, GLP-1 receptor agonists, and combination therapy in preventing kidney failure in type 2 diabetes","volume":"21","author":"Blum MF","year":"2026","unstructured":"Blum MF, Mehta S, Surapaneni A, et al.. A target trial emulation study of SGLT2 inhibitors, GLP-1 receptor agonists, and combination therapy in preventing kidney failure in type 2 diabetes. Clin J Am Soc Nephrol. 2026, 21:437-445. 10.2215\/CJN.0000000902","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams N","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, et al.. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024, 385:e078242. 10.1136\/bmj-2023-078242","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer SC","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, et al.. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021, 372:m4573. 10.1136\/bmj.m4573","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14008","article-title":"Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis","volume":"22","author":"Hussein H","year":"2020","unstructured":"Hussein H, Zaccardi F, Khunti K, et al.. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Obes Metab. 2020, 22:1035-1046. 10.1111\/dom.14008","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019, 139:2022-2031. 10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14598","article-title":"The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a Scandinavian cohort study","volume":"24","author":"Ueda P","year":"2022","unstructured":"Ueda P, Wintzell V, Dahlqwist E, et al.. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a Scandinavian cohort study. Diabetes Obes Metab. 2022, 24:473-485. 10.1111\/dom.14598","journal-title":"Diabetes Obes Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes","volume":"84","author":"Edmonston D","year":"2024","unstructured":"Edmonston D, Mulder H, Lydon E, et al.. Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes. J Am Coll Cardiol. 2024, 84:696-708. 10.1016\/j.jacc.2024.06.016","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno E","year":"2021","unstructured":"Patorno E, Pawar A, Bessette LG, et al.. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021, 44:826-835. 10.2337\/dc20-1464","journal-title":"Diabetes Care"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01258-x","article-title":"Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","volume":"20","author":"Lugner M","year":"2021","unstructured":"Lugner M, Sattar N, Miftaraj M, Ekelund J, Franz\u00e9n S, Svensson AM, Eliasson B. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovasc Diabetol. 2021, 20:67. 10.1186\/s12933-021-01258-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000001016","article-title":"Comparative effectiveness of SGLT2 inhibitor and GLP-1 receptor agonist on kidney and cardiovascular outcomes by kidney failure risk","volume":"37","author":"Hartsell SE","year":"2026","unstructured":"Hartsell SE, Wei G, Singh R, et al.. Comparative effectiveness of SGLT2 inhibitor and GLP-1 receptor agonist on kidney and cardiovascular outcomes by kidney failure risk. J Am Soc Nephrol. 2026, 37:1733-1747. 10.1681\/ASN.0000001016","journal-title":"J Am Soc Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.02.5123","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in diabetes mellitus","volume":"87","author":"Bu F","year":"2026","unstructured":"Bu F, Wu R, Ostropolets A, et al.. Comparative cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in diabetes mellitus. J Am Coll Cardiol. 2026, 87:2963-2977. 10.1016\/j.jacc.2026.02.5123","journal-title":"J Am Coll Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve SV","year":"2025","unstructured":"Badve SV, Bilal A, Lee MY, et al.. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025, 13:15-28. 10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000001033","article-title":"Target trial emulation: glucagon-like peptide-1 receptor agonist, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors for kidney outcome prevention","volume":"21","author":"Hung A","year":"2026","unstructured":"Hung A, Beck C, Greevy RA, Hackstadt AJ, Elasy TA, Roumie CL. Target trial emulation: glucagon-like peptide-1 receptor agonist, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors for kidney outcome prevention. Clin J Am Soc Nephrol. 2026, 21:997-1009. 10.2215\/CJN.0000001033","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen BL","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L, et al.. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation. 2024, 150:1781-1790. 10.1161\/CIRCULATIONAHA.124.071689","journal-title":"Circulation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15500","article-title":"Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents","volume":"26","author":"Kunutsor SK","year":"2024","unstructured":"Kunutsor SK, Zaccardi F, Balasubramanian VG, et al.. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Diabetes Obes Metab. 2024, 26:1837-1849. 10.1111\/dom.15500","journal-title":"Diabetes Obes Metab"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1486655","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis","volume":"16","author":"Wang Y","year":"2025","unstructured":"Wang Y, Wu H, Yang J, et al.. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis. Front Endocrinol (Lausanne). 2025, 16:1486655. 10.3389\/fendo.2025.1486655","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277321","article-title":"Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: propensity score matched analysis","volume":"17","author":"Sun W","year":"2022","unstructured":"Sun W, Kong AP, Yan BP. Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: propensity score matched analysis. PLoS One. 2022, 17:e0277321. 10.1371\/journal.pone.0277321","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang MH","year":"2024","unstructured":"Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024, 7:e2427258. 10.1001\/jamanetworkopen.2024.27258","journal-title":"JAMA Netw Open"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2026.0245","article-title":"Oral semaglutide and change in cardiovascular risk factors in high-risk type 2 diabetes: a post hoc secondary analysis of the SOUL randomized clinical trial","volume":"11","author":"Mulvagh SL","year":"2026","unstructured":"Mulvagh SL, Inzucchi SE, Marx N, et al.. Oral semaglutide and change in cardiovascular risk factors in high-risk type 2 diabetes: a post hoc secondary analysis of the SOUL randomized clinical trial. JAMA Cardiol. 2026, 11:427-437. 10.1001\/jamacardio.2026.0245","journal-title":"JAMA Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2116","article-title":"Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: findings from a population-based cohort study","volume":"43","author":"Adderley NJ","year":"2020","unstructured":"Adderley NJ, Subramanian A, Toulis K, et al.. Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: findings from a population-based cohort study. Diabetes Care. 2020, 43:1868-1877. 10.2337\/dc19-2116","journal-title":"Diabetes Care"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.50978","article-title":"Incretin receptor agonists and CPAP use in adults with diabetes, obesity, and obstructive sleep apnea","volume":"8","author":"Tang H","year":"2025","unstructured":"Tang H, Zhang B, Lu Y, Zhang D, Lu Y, Asch DA, Chen Y. Incretin receptor agonists and CPAP use in adults with diabetes, obesity, and obstructive sleep apnea. JAMA Netw Open. 2025, 8:e2550978. 10.1001\/jamanetworkopen.2025.50978","journal-title":"JAMA Netw Open"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1492","article-title":"Cost-effectiveness of newer pharmacologic treatments in adults with type 2 diabetes: a systematic review of cost-effectiveness studies for the American College of Physicians","volume":"177","author":"Schousboe JT","year":"2024","unstructured":"Schousboe JT, Landsteiner A, Drake T, et al.. Cost-effectiveness of newer pharmacologic treatments in adults with type 2 diabetes: a systematic review of cost-effectiveness studies for the American College of Physicians. Ann Intern Med. 2024, 177:633-642. 10.7326\/M23-1492","journal-title":"Ann Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2941","article-title":"First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study","volume":"175","author":"Choi JG","year":"2022","unstructured":"Choi JG, Winn AN, Skandari MR, et al.. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022, 175:1392-1400. 10.7326\/M21-2941","journal-title":"Ann Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07331-1","article-title":"Incidence and predictors of primary nonadherence to sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 agonists in a large integrated healthcare system","volume":"37","author":"Luo J","year":"2022","unstructured":"Luo J, Feldman R, Rothenberger S, Korytkowski M, Fischer MA, Gellad WF. Incidence and predictors of primary nonadherence to sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 agonists in a large integrated healthcare system. J Gen Intern Med. 2022, 37:3562-3569. 10.1007\/s11606-021-07331-1","journal-title":"J Gen Intern Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao Y","year":"2020","unstructured":"Gao Y, Peterson E, Pagidipati N. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. Am Heart J. 2020, 224:47-53. 10.1016\/j.ahj.2020.03.017","journal-title":"Am Heart J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69016-z","article-title":"Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors","volume":"14","author":"Liu J","year":"2024","unstructured":"Liu J, Su X, Hao Y, Liu J. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors. Sci Rep. 2024, 14:18290. 10.1038\/s41598-024-69016-z","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514464-cardiorenal-protection-in-type-2-diabetes-a-systematic-review-comparing-glucagon-like-peptide-1-receptor-agonists-and-sodium-glucose-cotransporter-2-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:35:29Z","timestamp":1789032929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514464-cardiorenal-protection-in-type-2-diabetes-a-systematic-review-comparing-glucagon-like-peptide-1-receptor-agonists-and-sodium-glucose-cotransporter-2-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":52,"URL":"https:\/\/doi.org\/10.7759\/cureus.116039","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}